Lupin launches Rivaroxaban Tablets in United States

08 Mar 2025 Evaluate

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the United States Food and Drug Administration (USFDA).

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD); and to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD. Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of $446 million in the U.S. (IQVIA MAT January 2025).  

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×